JP2011515337A5 - - Google Patents

Download PDF

Info

Publication number
JP2011515337A5
JP2011515337A5 JP2010548932A JP2010548932A JP2011515337A5 JP 2011515337 A5 JP2011515337 A5 JP 2011515337A5 JP 2010548932 A JP2010548932 A JP 2010548932A JP 2010548932 A JP2010548932 A JP 2010548932A JP 2011515337 A5 JP2011515337 A5 JP 2011515337A5
Authority
JP
Japan
Prior art keywords
group
optionally substituted
pharmaceutically acceptable
compound
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010548932A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011515337A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/035609 external-priority patent/WO2009108912A1/en
Publication of JP2011515337A publication Critical patent/JP2011515337A/ja
Publication of JP2011515337A5 publication Critical patent/JP2011515337A5/ja
Withdrawn legal-status Critical Current

Links

JP2010548932A 2008-02-29 2009-02-28 プロテインキナーゼモジュレーター Withdrawn JP2011515337A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6784508P 2008-02-29 2008-02-29
US61/067,845 2008-02-29
US10390808P 2008-10-08 2008-10-08
US61/103,908 2008-10-08
PCT/US2009/035609 WO2009108912A1 (en) 2008-02-29 2009-02-28 Protein kinase modulators

Publications (2)

Publication Number Publication Date
JP2011515337A JP2011515337A (ja) 2011-05-19
JP2011515337A5 true JP2011515337A5 (enExample) 2013-05-02

Family

ID=41016490

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010548932A Withdrawn JP2011515337A (ja) 2008-02-29 2009-02-28 プロテインキナーゼモジュレーター

Country Status (8)

Country Link
US (2) US8168651B2 (enExample)
EP (1) EP2259678A4 (enExample)
JP (1) JP2011515337A (enExample)
CN (1) CN102036561A (enExample)
AU (1) AU2009219154A1 (enExample)
CA (1) CA2716755A1 (enExample)
MX (1) MX2010009445A (enExample)
WO (1) WO2009108912A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2061765T3 (en) 2006-09-01 2015-01-26 Senhwa Biosciences Inc Serine-threonine protein kinase AND PARP-MODULATOR
SI2268618T1 (sl) 2008-03-03 2015-09-30 Novartis Ag Spojine in sestavki kot modulatorji aktivnosti TLR
US20100173013A1 (en) * 2009-01-08 2010-07-08 Denis Drygin Treatment of neoplastic disorders using combination therapies
SG175210A1 (en) * 2009-04-17 2011-11-28 Cylene Pharmaceuticals Inc Method of treating disorders associated with protein kinase ck2 activity
US9968574B2 (en) * 2009-05-15 2018-05-15 The University Of Kentucky Research Foundation Treatment of MCI and Alzheimer's disease
WO2011025859A1 (en) * 2009-08-26 2011-03-03 Cylene Pharmaceuticals, Inc. Condensed quinolines as protein kinase modulators
SI2473510T1 (sl) * 2009-09-03 2014-10-30 Bristol-Myers Squibb Company Jak2 inhibitorji in njihova uporaba za zdravljenje mieloproliferativnih bolezni in raka
AU2010295622A1 (en) * 2009-09-16 2012-05-10 Cylene Pharmaceuticals, Inc. Tricyclic compounds and pharmaceutical uses thereof
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
LT2496567T (lt) 2009-11-05 2017-11-27 Rhizen Pharmaceuticals S.A. Nauji benzopirano kinazės moduliatoriai
US8853235B2 (en) * 2009-11-23 2014-10-07 Senhwa Biosciences, Inc. Polymorphs and salts of a kinase inhibitor
US10106798B2 (en) 2010-01-05 2018-10-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) FLT3 receptor antagonists for the treatment or the prevention of pain disorders
US9109227B2 (en) 2010-01-05 2015-08-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) FLT3 receptor antagonists for the treatment or the prevention of pain disorders
TWI503323B (zh) * 2010-03-29 2015-10-11 Oncotherapy Science Inc 三環化合物以及含此化合物之ｐｂｋ抑制劑
PT2705029T (pt) 2011-05-04 2019-02-01 Rhizen Pharmaceuticals S A Novos compostos como moduladores de proteína quinases
CN102731431A (zh) * 2012-06-20 2012-10-17 盛世泰科生物医药技术(苏州)有限公司 一种5-溴噻唑-4-甲酸的制备方法
PT2870157T (pt) 2012-07-04 2017-11-27 Rhizen Pharmaceuticals S A Inibidores seletivos de delta pi3k
EP2943485B1 (en) 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
TWI662030B (zh) 2013-01-15 2019-06-11 英塞特控股公司 適用作ｐｉｍ激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
CN108341774B (zh) * 2017-01-25 2022-07-19 首药控股(北京)股份有限公司 取代的喹啉酮类抑制剂
WO2019090205A1 (en) 2017-11-06 2019-05-09 Snap Bio, Inc. Pim kinase inhibitor compositions, methods, and uses thereof
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
CN111936484A (zh) 2017-12-22 2020-11-13 拉文纳制药公司 作为磷脂酰肌醇磷酸激酶抑制剂的色烯并吡啶衍生物
US11071727B2 (en) 2018-01-26 2021-07-27 Northwestern University Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors
US11332476B2 (en) * 2018-04-03 2022-05-17 3Sm Biotron Inc. Fms-like tyrosine kinase inhibitors
SG11202104371XA (en) * 2018-11-15 2021-05-28 Nippon Shinyaku Co Ltd 1,3,4-oxadiazolone compound and pharmaceutical
CN109369526A (zh) * 2018-12-19 2019-02-22 桂林理工大学 一种两面针碱衍生物的合成方法及其抗肿瘤应用
GB201902759D0 (en) 2019-02-28 2019-04-17 Benevolentai Bio Ltd Compositions and uses thereof
TW202112784A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之𠳭唏并嘧啶衍生物
CN111320605A (zh) * 2020-03-09 2020-06-23 吉林工程技术师范学院 一种银催化的含氟菲啶衍生物的制备方法
CN113444084A (zh) * 2020-03-26 2021-09-28 东南大学 一类抗肿瘤化合物及其制备与用途
CN113444085B (zh) * 2020-03-26 2022-04-08 东南大学 一种具有克服顺铂耐药的抗肿瘤化合物及其制备与应用
JP2023520882A (ja) * 2020-03-30 2023-05-22 センホア・バイオサイエンシーズ・インコーポレイテッド 肝臓指向性のウイルス感染症、特にｂ型肝炎およびｄ型肝炎を処置するための抗ウイルス化合物および方法
EP3967307A1 (en) 2020-09-15 2022-03-16 Instytut Hematologii I Transfuzologii Use of pim kinase inhibitors to augment the efficacy of anti-cd20 antibody-based therapies in hematologic malignancies and non-malignant conditions
AU2021360636A1 (en) * 2020-10-16 2023-06-15 Shanghai De Novo Pharmatech Co., Ltd. Triheterocyclic derivative, and pharmaceutical composition and application thereof
GB202102895D0 (en) 2021-03-01 2021-04-14 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2023126951A1 (en) * 2022-01-03 2023-07-06 Yeda Research And Development Co. Ltd. Inhibitors of autophagy-related protein-protein interactions
WO2023225586A2 (en) * 2022-05-19 2023-11-23 4M Therapeutics Inc. Novel azaphenantrhene derivatives as inhibitors of glycogen synthase kinase 3 for therapeutic use
CN120641422A (zh) * 2023-02-03 2025-09-12 米拉蒂治疗公司 取代的三环化合物
US11987581B1 (en) 2023-12-19 2024-05-21 King Faisal University Imidazo[1,2-c]pyrido[3,4-e]pyrimidine-2-carboxylic acids as CK2 inhibitors
US12024518B1 (en) 2023-12-20 2024-07-02 King Faisal University Pyrazolo[4,3-C][1,6]naphthyridines as CK2 inhibitors
US12012414B1 (en) 2024-01-04 2024-06-18 King Faisal University Imidazo[1,5-a]pyrido[4,3-e]pyrimidines as CK2 inhibitors
US11964974B1 (en) 2024-01-08 2024-04-23 King Faisal University Imidazo[1,2-c]pyrido[3,4-e]pyrimidine-3-carboxylic acids as CK2 inhibitors
US11981676B1 (en) 2024-01-16 2024-05-14 King Faisal University Pyrazolo[4,3-c][2,6]naphthyridines as CK2 inhibitors
US12187726B1 (en) 2024-02-06 2025-01-07 King Faisal University Imidazo[1,5-a]pyrido[4,3-e]pyrazines as CK2 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991064A (en) * 1975-01-17 1976-11-09 Warner-Lambert Company Benzonaphthyridines
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
MY148521A (en) * 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
WO2007007152A2 (en) 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat metastatic cancers and chloroma
MX2008002165A (es) * 2005-08-16 2008-04-29 Irm Llc Compuestos y composiciones como inhibidores de la proteina cinasa.
BRPI0619785A2 (pt) * 2005-12-13 2011-10-18 Wyeth Corp composto, composição e método para o tratamento de um transtorno proliferativo e método de prepraração
DK2061765T3 (en) * 2006-09-01 2015-01-26 Senhwa Biosciences Inc Serine-threonine protein kinase AND PARP-MODULATOR
CA2663856A1 (en) 2006-09-28 2008-04-10 Exelixis, Inc. Jak-2 modulators and methods of use
WO2008109613A1 (en) * 2007-03-05 2008-09-12 Wyeth Benzo[c][2,7]naphthyridine derivatives, and their use as kinase inhibitors

Similar Documents

Publication Publication Date Title
AU2015276537B2 (en) Novel compounds as dual inhibitors of histone methyltransferases and dna methyltransferases
JP5976778B2 (ja) キナーゼ阻害剤としてのピラゾリル−ピリミジン誘導体
US9283224B2 (en) Substituted pyrimidinyl-pyrroles active as kinase inhibitors
JP6215832B2 (ja) アミノピリミジンキナーゼ阻害剤
RU2011124304A (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2019527725A (ja) ４位置換アミノイソキノリン誘導体
JP2010529140A (ja) サイクリン依存性キナーゼの選択的阻害剤
TW201808888A (zh) 整合應激途徑之調節劑
KR20180017013A (ko) K-Ras 조절제
JP2017528502A5 (enExample)
JP2010502651A5 (enExample)
JP2019077713A5 (enExample)
RU2014115847A (ru) Пирролопиримидиновые соединения для лечения злокачественной опухоли
JP2012520288A (ja) ピラゾロ［１，５−ａ］−１，３，５−トリアジン誘導体、その調製、及びその治療的使用方法
JP2013538213A5 (enExample)
RU2013112871A (ru) Соединения для лечения рака
CN108794453A (zh) 一种靶向降解fak蛋白的化合物及其应用
EP2890379A2 (en) Benzothiazole or benzoxazole compounds as sumo activators
JP2020509997A5 (enExample)
JP6542236B2 (ja) 有機化合物
WO2020006724A1 (zh) 一种靶向降解fak蛋白的化合物及其应用
RU2011136855A (ru) Производные бензотиазолов и бензимидазолов, содержащие 6-nh-замещенные триазолопиридазинсульфанил в положении 6: получение, применение в качестве лекарственных средств и применение в качестве ингибиторов мет
CN111039941B (zh) 一种含氮杂环化合物、其制备方法及应用
JP2018058863A (ja) キナーゼ阻害活性を有するトリプトリン誘導体及びその使用
CN119490450A (zh) 一种含肟化合物及其用途